TODAY, WE CELEBRATE: THIS WEEK’S GOOD NEWS FOR GLOBAL EQUITY

TODAY, WE CELEBRATE: THIS WEEK’S GOOD NEWS FOR GLOBAL EQUITY

News
WEEKLY COVID VACCINE RESEARCH UPDATE TUESDAY, MARCH 2, 2021 Data Updates High-income country confirmed dose total: 4.6 billion Upper-middle-income country total: 1.3 billion Lower-middle-income country total: 597 million Low-income country total: 670 million COVAX total: 1.12 billion Total worldwide confirmed purchases of Covid-19 vaccines: 8.2 billion doses Weekly Insights and Interesting Trends Author: Andrea Taylor Today, we celebrate: This week’s good news for global equity There were two significant developments this week that are great news for Covid-19 vaccine equity. To be clear, the picture is still bleak: rich countries hold more than half of the vaccine purchased and don’t want to share until they’ve had their fill. More than 100 countries have not administered their first vaccinations, even while coverage passed 90% in Israel, 60% in the UAE, and…
Read More
RHETORIC FIRST, ACTION LATER: THE G7 APPROACH TO GLOBAL EQUITY

RHETORIC FIRST, ACTION LATER: THE G7 APPROACH TO GLOBAL EQUITY

News
WEEKLY COVID VACCINE RESEARCH UPDATE MONDAY, FEBRUARY 22, 2021 Data Updates High-income country confirmed dose total: 4.6 billion Upper-middle-income country total: 1.3 billion Lower-middle-income country total: 631 million Low-income country total: 671 million COVAX total: 1.12 billion Total worldwide confirmed purchases of Covid-19 vaccines: 8.25 billion doses Weekly Insights and Interesting Trends Author: Andrea Taylor Rhetoric first, action later: the G7 approach to global equity The G7 countries met (virtually) on Friday, February 19, to share variants of “no one is safe until everyone is safe” and discuss the importance of global equity of Covid-19 vaccines and the need for international cooperation. (Sound familiar? That’s because we heard the same things from the G20 in November.) The countries together pledged another $7.5 billion in funding for COVAX (including the $4 billion that the US Congress set aside for…
Read More
VACCINE HESITANCY WILL SOON BECOME THE PRIMARY OBSTACLE TO GLOBAL IMMUNITY

VACCINE HESITANCY WILL SOON BECOME THE PRIMARY OBSTACLE TO GLOBAL IMMUNITY

News
WEEKLY COVID VACCINE RESEARCH UPDATE TUESDAY, FEBRUARY 16, 2021 Data Updates High-income country confirmed dose total: 4.6 billion Upper-middle-income country total: 1.2 billion Lower-middle-income country total: 599 million Low-income country total: 670 million COVAX total: 1.12 billion Total worldwide confirmed purchases of Covid-19 vaccines: 8.2 billion doses Weekly Insights and Interesting Trends Author: Andrea Taylor Vaccine hesitancy will soon become the primary obstacle to global immunity Global manufacturing capacity has been the primary rate limiter for Covid-19 vaccinations. Our vaccine manufacturing infrastructure was not designed to produce enough doses to cover 70% of the world’s population within a year (in addition to regular and routine vaccines) and, as expected, demand is outstripping supply. There has been good news on the manufacturing front, however, with several large pharma companies recently joining with…
Read More
COVAX RELEASED DRAFT ALLOCATIONS FOR THE FIRST HALF OF 2021

COVAX RELEASED DRAFT ALLOCATIONS FOR THE FIRST HALF OF 2021

News
WEEKLY COVID VACCINE RESEARCH UPDATE MONDAY, FEBRUARY 8, 2021 Data Updates High-income country confirmed dose total: 4.2 billion Upper-middle-income country total: 1.2 billion Lower-middle-income country total: 582 million Low-income country total: 670 million COVAX total: 1.11 billion Total worldwide confirmed purchases of Covid-19 vaccines: 7.8 billion doses Weekly Insights and Interesting Trends Author: Andrea Taylor COVAX released draft allocations for the first half of 2021 The COVAX partnership released last week its first estimates of dose allocations for participating countries, covering planned deliveries from February through June. These are labeled as “indicative,” meaning the estimates are non-binding and subject to a list of caveats provided in both the distribution forecast and the supply update released in January. In fact, the language surrounding both documents seems on balance to contain more hedging than forecasting. This is…
Read More
WHAT IS AT STAKE IN EU’S MOVE TO CONTROL VACCINE EXPORTS

WHAT IS AT STAKE IN EU’S MOVE TO CONTROL VACCINE EXPORTS

News
WEEKLY COVID VACCINE RESEARCH UPDATE MONDAY, FEBRUARY 1, 2021 [caption id="attachment_1474" align="alignnone" width="329"] Source: © WHO / Gregor Donaldson[/caption] Data Updates High-income country confirmed dose total: 4.2 billion Upper-middle-income country total: 1.2 billion Lower-middle-income country total: 524 million Low-income country total: 670 million COVAX total: 1.11 billion Total worldwide confirmed purchases of Covid-19 vaccines: 7.2 billion doses Weekly Insights and Interesting Trends Author: Andrea Taylor What is at Stake in EU’s Move to Control Vaccine Exports AstraZeneca recently alerted the EU that it would only be able to deliver 25% of the 80-100 million doses of Covid-19 vaccine expected this quarter, due to production problems in the European plants. The EU responded by suggesting, in the firmest of tones, that AstraZeneca divert doses from the (recently Brexited) UK manufacturing plants…
Read More
THE US FORMALLY JOINED COVAX. WILL IT MATTER?

THE US FORMALLY JOINED COVAX. WILL IT MATTER?

News
WEEKLY COVID VACCINE RESEARCH UPDATE MONDAY, JANUARY 25, 2021 Data Updates High-income country confirmed dose total: 4.2 billion Upper-middle-income country total: 1.14 billion Lower-middle-income country total: 444 million Low-income country total: 270 million COVAX total: 1.11 billion Total worldwide confirmed purchases of Covid-19 vaccines: 7.2 billion doses Weekly Insights and Interesting Trends Author: Andrea Taylor The US formally joined COVAX. Will it Matter? Dr. Anthony Fauci, newly named the US Chief Medical Advisor, warmly addressed the WHO executive board within the first 24 hours of the Biden administration. Dr. Fauci confirmed that under President Joe Biden, the US will rejoin the WHO and will also join COVAX, the global mechanism designed to ensure equitable allocation of vaccines across the world. The value of this move may be largely symbolic at this point. The…
Read More
DIRECT COVID VACCINE DEALS BY POORER COUNTRIES ARE AN IMPORTANT AND ENCOURAGING DEVELOPMENT

DIRECT COVID VACCINE DEALS BY POORER COUNTRIES ARE AN IMPORTANT AND ENCOURAGING DEVELOPMENT

News
WEEKLY COVID VACCINE RESEARCH UPDATE TUESDAY, JANUARY 19, 2021 Data Updates High-income country confirmed dose total: 4.2 billion Upper-middle-income country total: 1.12 billion Lower-middle-income country total: 411 million Low-income country total: 270 million COVAX total 1.07 billion Total worldwide confirmed purchases of Covid-19 vaccines: 7.4 billion doses Weekly Insights and Interesting Trends Author: Andrea Taylor Direct deals by poorer countries are an important and encouraging development This past week, we saw the first direct vaccine purchases made for low-income countries with the African Union’s purchase of 270 million doses of Covid-19 vaccines from Pfizer-BioNTech, OxfordAstraZeneca, and Johnson & Johnson (J&J). A relatively modest purchase of 270 million doses, when 7 billion doses have already been bought, might be overlooked but it actually represents a significant shift in the global power…
Read More
CHANGING HOW INDIA’S VACCINE NUMBERS ARE REPRESENTED IN OUR DATA

CHANGING HOW INDIA’S VACCINE NUMBERS ARE REPRESENTED IN OUR DATA

News
WEEKLY COVID VACCINE RESEARCH UPDATE MONDAY, JANUARY 11, 2021 Data Updates High-income country confirmed dose total: 4.2 billion Upper-middle-income country total: 1.24 billion Lower-middle-income country total: 495 million Low-income country total: 0 COVAX total: 1.07 billion Total worldwide confirmed purchases of Covid-19 vaccines: 7 billion doses Weekly Insights and Interesting Trends Author: Andrea Taylor Changing how India's vaccine numbers are represented in our data We have changed this week the way that India’s reserved doses of vaccine are represented in our data, moving the majority of the doses out of “confirmed” to “potential” doses. The way we have been counting India’s numbers in past weeks is a bit different than for other countries. Our numbers typically come from publicly reported purchases by governments (and occasionally private sector buyers). But because…
Read More
TRACKING COVID VACCINE REGULATORY APPROVALS AROUND THE WORLD

TRACKING COVID VACCINE REGULATORY APPROVALS AROUND THE WORLD

News
WEEKLY COVID VACCINE RESEARCH UPDATE FRIDAY, DECEMBER 18, 2020 Data Updates High-income country confirmed dose total: 4 billion Upper-middle-income country total: 1.1 billion Lower-middle-income country total: 1.8 billion Low-income country total: 0 COVAX total: 870 million Total worldwide confirmed purchases of Covid-19 vaccines: 7.7 billion doses Weekly Insights and Interesting Trends Author: Andrea Taylor Tracking regulatory approvals around the world We have seen a lot of movement in regulatory approval of Covid-19 vaccines over the past two weeks, as vaccination campaigns begin to roll out. When tracking the Covid-19 vaccine landscape, it is important to keep in mind the difference between emergency use authorization and full authorization. Most Covid-19 vaccine approvals received thus far have been limited to emergency use. This may be granted to address a health emergency, on…
Read More
WHAT ARE THE LATEST DEVELOPMENTS WITH VACCINES DEVELOPED IN RUSSIA AND CHINA?

WHAT ARE THE LATEST DEVELOPMENTS WITH VACCINES DEVELOPED IN RUSSIA AND CHINA?

News
WEEKLY COVID VACCINE RESEARCH UPDATE MONDAY, DECEMBER 14, 2020 Data Updates High-income country confirmed dose total: 3.9 billion Upper-middle-income country total: 1 billion Lower-middle-income country total: 1.8 billion Low-income country total: 0 COVAX total: 700 million Total worldwide confirmed purchases of Covid-19 vaccines: 7.4 billion doses Weekly Insights and Interesting Trends Author: Andrea Taylor What are the latest developments with vaccines developed in Russia and China? We are frequently asked why some data about vaccines purchased by Russia and China appear to be missing from our data. The answer is because both countries control largely state-owned vaccine development and manufacturing chains, and, in part because of this, are notably less transparent than some other countries about advance purchases for domestic use as well as exports. Our dataset includes publicly announced…
Read More